- Home
- ITCI vs INSM Comparison
ITCI vs INSM Comparison
Compare ITCI & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITCI
- INSM
- Stock Information
- Founded
- ITCI 2002
- INSM 1988
- Country
- ITCI United States
- INSM United States
- Employees
- ITCI N/A
- INSM N/A
- Industry
- ITCI Biotechnology: Pharmaceutical Preparations
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- ITCI Health Care
- INSM Health Care
- Exchange
- ITCI Nasdaq
- INSM Nasdaq
- Market Cap
- ITCI 13.5B
- INSM 14.3B
- IPO Year
- ITCI N/A
- INSM 2000
- Fundamental
- Price
- ITCI $131.36
- INSM $75.07
- Analyst Decision
- ITCI Buy
- INSM Strong Buy
- Analyst Count
- ITCI 13
- INSM 16
- Target Price
- ITCI $106.58
- INSM $94.64
- AVG Volume (30 Days)
- ITCI 2.2M
- INSM 2.0M
- Earning Date
- ITCI 05-06-2025
- INSM 02-20-2025
- Dividend Yield
- ITCI N/A
- INSM N/A
- EPS Growth
- ITCI N/A
- INSM N/A
- EPS
- ITCI N/A
- INSM N/A
- Revenue
- ITCI $680,852,000.00
- INSM $363,707,000.00
- Revenue This Year
- ITCI $40.64
- INSM $30.31
- Revenue Next Year
- ITCI $58.53
- INSM $118.39
- P/E Ratio
- ITCI N/A
- INSM N/A
- Revenue Growth
- ITCI 46.62
- INSM 19.17
- 52 Week Low
- ITCI $63.30
- INSM $21.92
- 52 Week High
- ITCI $131.37
- INSM $84.91
- Technical
- Relative Strength Index (RSI)
- ITCI 85.33
- INSM 44.92
- Support Level
- ITCI $131.19
- INSM $71.57
- Resistance Level
- ITCI $131.37
- INSM $76.31
- Average True Range (ATR)
- ITCI 0.26
- INSM 3.28
- MACD
- ITCI -0.55
- INSM -0.72
- Stochastic Oscillator
- ITCI 99.70
- INSM 28.88
About ITCI Intra-Cellular Therapies Inc.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
About INSM Insmed Incorporated
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.